Recon: EMA recommends boosters targeting Omicron BA.4/5; FDA funding negotiations heat up as deadline looms
ReconMichael Mezher
BiologicsBiotechnologyDiagnosticsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyReconMichael MezherBiologicsBiotechnologyDiagnosticsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy